The role of tau in the pathological process and clinical expression of Huntington's disease. by Vuono, Romina et al.
The role of tau in the pathological process and
clinical expression of Huntington’s disease
Romina Vuono,1 Sophie Winder-Rhodes,1,2 Rohan de Silva,3 Giulia Cisbani,4
Janelle Drouin-Ouellet,1 REGISTRY Investigators of the European Huntington’s Disease
Network,* Maria G. Spillantini,1 Francesca Cicchetti4,5 and Roger A. Barker1
Membership of the REGISTRY Investigators of the European Huntington’s Disease Network is provided in the online
Supplementary material.
Huntington’s disease is a neurodegenerative disorder caused by an abnormal CAG repeat expansion within exon 1 of the huntingtin
gene HTT. While several genetic modiﬁers, distinct from the Huntington’s disease locus itself, have been identiﬁed as being linked to
the clinical expression and progression of Huntington’s disease, the exact molecular mechanisms driving its pathogenic cascade and
clinical features, especially the dementia, are not fully understood. Recently the microtubule associated protein tau, MAPT, which is
associated with several neurodegenerative disorders, has been implicated in Huntington’s disease. We explored this association in
more detail at the neuropathological, genetic and clinical level. We ﬁrst investigated tau pathology by looking for the presence of
hyperphosphorylated tau aggregates, co-localization of tau with mutant HTT and its oligomeric intermediates in post-mortem brain
samples from patients with Huntington’s disease (n = 16) compared to cases with a known tauopathy and healthy controls. Next, we
undertook a genotype–phenotype analysis of a large cohort of patients with Huntington’s disease (n = 960) with a particular focus on
cognitive decline. We report not only on the tau pathology in the Huntington’s disease brain but also the association between genetic
variation in tau gene and the clinical expression and progression of the disease. We found extensive pathological inclusions containing
abnormally phosphorylated tau protein that co-localized in some instances with mutant HTT. We conﬁrmed this related to the
disease process rather than age, by showing it is also present in two patients with young-onset Huntington’s disease (26 and 40 years
old at death). In addition we demonstrate that tau oligomers (suggested to be the most likely neurotoxic tau entity) are present in the
Huntington’s disease brains. Finally we highlight the clinical signiﬁcance of this pathology by demonstrating that the MAPT haplo-
types affect the rate of cognitive decline in a large cohort of patients with Huntington’s disease. Our ﬁndings therefore highlight a
novel important role of tau in the pathogenic process and clinical expression of Huntington’s disease, which in turn opens up new
therapeutic avenues for this incurable condition.
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Introduction
Huntington’s disease is an autosomal dominant neurode-
generative disorder characterized by motor, psychiatric
and cognitive deﬁcits. Cognitive impairment appears early
in the disease course, often leading to dementia which pro-
foundly impacts on quality of life (Ready et al., 2008;
Novak and Tabrizi, 2011). Huntington’s disease is caused
by an abnormal CAG repeat expansion within exon 1 of
the human huntingtin gene (HTT) (Gusella et al., 1983)
encoding the huntingtin (HTT) protein. The expansion
results in a mutant HTT protein, which forms oligomers
and globular intermediates that give rise to aggregates asso-
ciated with widespread neuronal dysfunction and neurode-
generation, particularly within the cerebral cortex and
striatum. Although there is a correlation between CAG
repeat length and age at onset of motor features (The
Huntington’s Disease Collaborative Group, 1993; Ranen
et al., 1995; Zuccato et al., 2010), patients with
Huntington’s disease differ dramatically in their age at
onset, initial disease manifestations and progression, despite
similar CAG repeat length. Several studies have identiﬁed a
large set of possible genes (Zuccato et al., 2010), distinct
from the Huntington’s disease locus itself, that could
modify the disease manifestation and progression but
their relevance remains unclear. As such there is a need
to ﬁnd other genes and/or genetic variants, which will pro-
vide novel clues to the complex pathogenesis of
Huntington’s disease. One such candidate is the microtu-
bule-associated protein tau (MAPT) gene.
The MAPT gene is localized on chromosome 17q21 and
is represented by two haplotype clades, the more common
H1 haplotype and the rarer H2 haplotype, which result
from a large (970kb) chromosomal inversion
(Stefansson et al., 2005). The H1 haplotype has been con-
sistently shown to be a strong genetic risk factor for pro-
gressive supranuclear palsy, corticobasal degeneration
(Baker et al., 1999; Houlden et al., 2001) and we have
previously shown that it is also associated with the earlier
development of dementia in Parkinson’s disease (Goris
et al., 2007; Williams-Gray et al., 2009).
The adult human brain expresses six isoforms of the tau
(MAPT) protein, which is involved in microtubule assembly,
stabilization, neuronal morphogenesis, and axonal transport
(Spillantini and Goedert, 2013). Alternative splicing of exon
10 results in isoforms with three (3R) or four (4R) carboxy-
terminal microtubule-binding repeat domains expressed in
approximately equal amount in the CNS of healthy adults
(Goedert et al., 1989). Mutations and common genetic
variants of the MAPT gene have been associated with the
development of tauopathies as well as to imbalances in the
4R:3R tau isoform ratio which may contribute to tau hyper-
phosphorylation, aggregation and pathology (Anfossi et al.,
2011; Spillantini and Goedert, 2013).
Recently it has been shown that there is an increase in
the 4R:3R tau isoform ratio, with nuclear rod-like tau
deposits (TNRs) in Huntington’s disease post-mortem
brain samples as well as an attenuated motor phenotype
in mutant HTT transgenic mice with genetic tau reduction
(Ferna´ndez-Nogales et al., 2014). Subsequently, it has been
shown that, in transgenic Huntington’s disease mouse
models, mutant HTT alters tau phosphorylation (Blum
et al., 2015; Gratuze et al., 2015) which is known to be
a characteristic of insoluble paired helical ﬁlaments that
form neuroﬁbrillary tangles (Grundke-Iqbal et al., 1986;
Kosik et al., 1986; Wood et al., 1986; Goedert et al.,
1988, 1992). Indeed, neuroﬁbrillary tangles have been de-
tected in Huntington’s disease brains (Jellinger, 1998) al-
though these ﬁndings were attributed to co-incidental
Alzheimer’s disease (Davis et al., 2014).
Given all this, there is still debate surrounding the ques-
tion of whether tau aggregates and their level of phosphor-
ylation affect the expression and/or progression of
Huntington’s disease (Herna´ndez and Avila, 2008;
Caparros-Lefebvre et al., 2009). In this study, we set out
to answer this question by ﬁrst of all ascertaining whether
there are hyperphosphorylated tau aggregates in cortical
and striatal tissues from patients with Huntington’s disease,
with comparison to cases with a known tauopathy
(Alzheimer’s disease, progressive supranuclear palsy,
Pick’s disease and corticobasal degeneration) and healthy
control subjects. We then sought to conﬁrm the presence
of pathological tau in patients with young-onset
Huntington’s disease (26 and 40 years old at death) to
show that the ﬁndings were linked to the disease and not
old age. Finally we investigated the relationship between
MAPT haplotypes and the clinical progression of the dis-
ease, with a focus on cognitive decline, by performing a
genotype–phenotype analysis in a large cohort of individ-
uals with Huntington’s disease.
Materials and methods
Ethics statement
The study was approved by the Local Research
Ethics Committee and the other sites of the European
Huntington Disease Network (EHDN) REGISTRY project
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(Orth et al., 2011). The participants and/or the next of kin
gave informed written consent for the use of genetic material
and brain tissue for research according to International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use-Good Clinical
Practice (ICH-GCP) guidelines (http://www.ich.org/LOB/
media/MEDIA482.pdf) and the Declaration of Helsinki.
Subjects
Human genetic material, clinical information and CAG repeat
length data were obtained from the European Huntington’s
Disease Network (EHDN) REGISTRY (Orth et al., 2011;
http://www.euro-hd.net/html/registry). Data were available
from 960 patients who had a clinical and genetically conﬁrmed
diagnosis of Huntington’s disease. Age at onset was deﬁned
as the age at which their ﬁrst Huntington’s disease features
appeared as judged by a trained neurologist either from
the neurological examination or (more frequently) from the
patient history as recorded in REGISTRY. Motor, functional
and cognitive features were scored at visits 1 year apart
using the Uniﬁed Huntington Disease Rating Scale
(UHDRS’99; Huntington Study Group, 1996). Cognitive
assessments included tests of verbal ﬂuency, the digit-symbol
modality test and the Stroop test (word, colour and
interference subtests), all of which are known to be sensitive
to the disease process in Huntington’s disease (Ho et al.,
2002).
The Cambridge Brain Bank provided anonymous post-
mortem brain samples (fresh-frozen and parafﬁn-embedded
tissues) from Huntington’s disease and sporadic tauopathy
cases as well as healthy age-matched controls known not to
have any neurological or psychiatric disorder (Table 1).
Cortical and striatal tissue was available for all cases.
Clinical data were retrospectively obtained from the clinical
charts available at the Brain Bank and are summarized in
Table 1. All the Huntington’s disease cases and healthy con-
trols were assessed by a neuropathologist to ensure they were
free of any Alzheimer’s disease pathology according to stand-
ard criteria based on tau pathology and amyloid-b deposition
(Braak and Braak, 1991).
The pathological severity of Huntington’s disease was scored
according to the Vonsattel grading system (Vonsattel et al.,
1985; Vonsattel and DiFiglia, 1998).
Immunohistochemistry
Immunohistochemistry was performed on 10 -mm thick
parafﬁn-embedded sections from cortical and striatal
Huntington’s disease brains using monoclonal mouse anti-
HTT and anti-tau antibodies and following standard proto-
cols. Deparafﬁnized and rehydrated tissue sections were incu-
bated overnight at 4C with the primary antibodies listed in
Supplementary Table 1.
Sections to be stained with both RD3 and RD4 antibodies,
speciﬁc for 3R- and 4R-tau isoforms, respectively (de Silva
et al., 2003), required pretreatment (antigen retrieval) by
microwaving in 10mM sodium citrate buffer (pH 6, 0.05%
Tween 20) for 20min. The labelling was visualized with the
ABC Elite Vectastain Kit (Vector laboratories). Brieﬂy, sec-
tions were incubated for 2 h at room temperature with the
biotinylated secondary antibody (1:500) and, following
washes in PBS, horseradish peroxidase Avidin-D was added
for 1 h at room temperature and visualized with 3-3’diamino-
benzidine as the chromogen.
Controls omitting the primary reagent were included in all
the experiments and were consistently negative for any stain-
ing. Pre-adsorption controls with 3R- and 4R-tau isoforms
were also carried out and found to be negative. Furthermore,
the immunohistochemistry performed on healthy control brain
sections using all the tau antibodies (Supplementary Table 1)
was also negative (Supplementary Fig. 1).
Immunofluorescence
The experimental procedure was based on previously pub-
lished protocols (Cisbani et al., 2013; Cicchetti et al., 2014).
In brief, prior to immunostaining, sections were deparafﬁnized
in CitrisolvTM (Fisherbrand), rehydrated and incubated over-
night at room temperature in blocking solutions containing the
primary antibodies listed in Supplementary Table 1. After
KPBS washes, sections were incubated with appropriate sec-
ondary antibodies in a blocking solution for 2 h at room
temperature (Goat anti-mouse Alexa Fluor 488, 1:750;
Goat anti-rabbit Alexa Fluor 546, 1:500; Goat anti-chicken
Alexa Fluor 647, 1:500; all Life Technologies).
Following DAPI incubation (2mg/ml, Molecular Probes),
sections were washed and coverslipped with Fluoromount-
GTM (SouthernBiotech). Confocal laser scanning microscopy
was performed using an Olympus FV500 confocal laser-
scanning microscope. Images were acquired by sequential scan-
ning and optimized by a two-frame Kalman ﬁlter and analysed
using acquisition software from Olympus (Fluoview SV500
imaging software 4.3, Olympus) and ImageJ (NIH).
Immunoblotting
Preparation of soluble and insoluble tau fractions from
Huntington’s disease, tauopathy and control brains was
adapted from previously published methods (Goedert et al.,
1989; Goedert and Jakes, 1990; Hanger et al., 2002).
Protein samples were dephosphorylated using -protein phos-
phatase (NEB) at a ﬁnal concentration of 20U/ml for 3 h at
30C. Dephosphorylation reactions were stopped by the add-
ition of LDS sample buffer (Life Technologies) followed by
heating at 70C for 10min. Samples were centrifuged at
10 000 g (av) before separation on NuPAGE 4–12% Bis-Tris
gels (Life Technologies) alongside a recombinant tau protein
ladder (rPeptide). Proteins were transferred to a nitrocellulose
membrane and probed with the phosphorylation-dependent
anti-tau mouse monoclonal antibody AT8 (1:1000,
ThermoScientiﬁc) and a rabbit polyclonal antiserum anti-
total tau (Dako, 1:20 000). Blots were visualized and quanti-
ﬁed using an Odyssey Infrared imaging system (LI-COR
Biosciences).
RNA isolation and quantitative
RT-PCR of tau isoform mRNAs
Total RNA was extracted from the cortical and striatal
Huntington’s disease and control brains (200–300mg) using
the RNeasy Lipid Tissue Midi kit according to the manufac-
turer’s protocol (Qiagen). The RT-PCR was performed on
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500ng of RNA in a volume of 50 ml by using the Qiagen
Onestep RT-PCR according to standard procedures. The 4R
and 3R MAPT transcripts were isolated using speciﬁc oligo-
nucleotides (ForE9 50-CTCCAAAATCAGGGGATCGC-30,
RevE12 50-TTTTTATTTCCTCCGCCAG-30) (Sigma) as
described in Anfossi et al. (2011). PCR products were sepa-
rated by electrophoresis in 1% (w/v) agarose gel. The intensity
of the bands was measured and the percentage of products
corresponding to the 4R and 3R MAPT transcripts was calcu-
lated. For all quantitative experiments, RT-PCR reactions were
carried out in three independent experiments. Statistical signiﬁ-
cance was ***P5 0.05, two-tailed t-test.
Genetics
Single nucleotide polymorphism (SNP) genotyping for rs9468,
tagging the MAPT H1 versus H2 haplotype, was performed
using the TaqMan allelic discrimination assay on an HT7900
sequence detection system (Applied Biosystem), according to
the manufacturer’s instructions. Genotyping success rates
were 496%. There were no inconsistencies amongst 192 sam-
ples genotyped in duplicate.
The CAG size in the HTT gene was determined for all the
Huntington’s disease and control brain samples by DNA
sequencing at the Laragen’s Sanger Sequencing Services (CA)
using the GeneMapper Software-Applied Biosystem. The
results are reported in Table 1.
Statistical analysis
A 2 test was used to compare the allele frequency of each
variant with that expected for a population in Hardy-
Weinberg equilibrium. Fisher’s exact test was used to compare
H1/H1, H1/H2 and H2/H2 genotype distribution. Only geno-
typed individuals for whom a complete data set was available
for at least two visits, a minimum of 1 year apart, were
included in the analysis. These participants were divided into
two groups on the basis of their MAPT genotype (H1 homo-
zygotes and H2 carriers) as described previously (Goris et al.,
2007; Williams-Gray et al., 2009). Baseline demographic
and clinical data were compared between groups using
two-tailed t-tests (two groups) and ANOVAs (more than two
groups).
The primary outcome of interest was the annual change in
cognitive performance based on a ‘composite cognitive score’,
a sum of individual scores in the Verbal Fluency, the Symbol
Digit and all parts of the Stroop test (colour, word and inter-
ference). Rate of change (points/year) was calculated by
Table 1 Huntington’s disease, tauopathy and control cases
Cases Gender Age (years) Grade (0–4) CAGn Repeats CAGn Repeats
Huntington’s disease
HD1 M 71 1 19 46
HD2 M 61 2 17 46
HD3 F 78 2 17 43
HD4 M 57 3 19 47
HD5 F 64 4 19 45
HD6 M 60 1 23 46
HD7 M 71 1 17 44
HD8 F 61 2 19 46
HD9 M 66 3 17 45
HD10 M 77 3 24 43
HD11 M 77 3 19 43
HD12 M 73 3 21 45
HD13 M 68 4 19 45
HD14 M 58 4 20 48
HD15 M 40 4 18 51
HD16 F 26 4 22 70
F:M 4:12 Average 63  13.80
Sporadic tauopathies
AD F 78 18 18
PSP M 75 20 20
PiD F 68 19 24
CBD M 79 28 33
F:M 2:2 Average 75  4.97
Controls
CTL1 M 67 0 20
CTL2 M 72 0 21
CTL3 M 69 0 20
CTL4 M 80 0 20
CTL5 F 83 0 19
F:M 1:4 Average 74.2  6.98
AD = Alzheimer’s disease; CBD = corticobasal degeneration; PiD = Pick’s disease; PSP = progressive supranuclear palsy.
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subtracting cognitive score at the ﬁrst assessment from the
score at the last follow-up assessment (or most complete
data set) divided by the time between these assessments in
years, as we have done previously (Goris et al., 2007;
Williams-Gray et al., 2009). Because the summed cognitive
score will be heavily weighted by inclusion of the three
Stroop assessments, change in performance was also calculated
for Verbal Fluency, Symbol Digit tests and Stroop (colour,
word and interference) sub-tests individually. Our secondary
outcome measure was the rate of change in motor decline,
calculated using the total motor score from the UHDRS’99
collected at the same visits as described above using an equiva-
lent formula.
Outliers were identiﬁed and the data were winsorized using
Tukey’s Hinge estimates. The difference in the distributions of
rate of cognitive and motor changes per year between genetic
groups was ﬁrst evaluated non-parametrically using Mann-
Whitney U-tests (two subgroups). Following this, a multivari-
ate linear regression was used to compare genetic groups with
the addition of relevant covariates including CAG repeat
length, gender, age at ﬁrst assessment and years since motor
onset at ﬁrst assessment. Correlations with continuous vari-
ables (CAG repeat length) were explored non-parametrically
using Kendall’s taub tests (two-tailed). All analyses were per-




tau aggregates in cortical and striatal
Huntington’s disease tissues
In an effort to assess tau phosphorylation and pathology in
the Huntington’s disease brain, immunohistochemical ana-
lyses using the AT8 monoclonal antibody against abnor-
mally phosphorylated tau were performed. Several AT8-
positive neuronal inclusions, including ring-like perinuclear,
ﬂame-shaped and globular inclusions (Yoshida, 2006;
Spillantini and Goedert, 2013) were found in the
Huntington’s disease cortex and striatum (Fig. 1A). In
particular, the insular cortex contained the greatest density
of hyperphosphorylated tau aggregates, which were distrib-
uted throughout all the cellular layers (primarily layers II to
VI) with the nucleus accumbens and inferior/anterior
putamen being the site of greatest tau pathology in the
striatum.
The speciﬁcity of the AT8 staining was conﬁrmed in
known tauopathy cases (Supplementary Fig. 2). In addition,
AT8-positive tufted astrocytes, astrocytic plaques, numer-
ous neuropil threads, dots (Fig. 1A) and nuclear rod-like
tau deposits (Ferna´ndez-Nogales et al., 2014) were also
detected among the AT8-positive inclusions (Fig. 1B).
Importantly, AT8-positive tau aggregates were also present
in both the younger Huntington’s disease cases (26 and 40
years old at death) (Fig. 1C).
Oligomeric tau inclusions in striatal
Huntington’s disease tissues
Having found abnormal tau phosphorylation in both cor-
tical and striatal regions of Huntington’s brains, we next
looked for the presence of tau oligomers by using T22 and
TOMA antibodies, which are speciﬁc for oligomeric tau
intermediates (Gerson and Kayed, 2013; Castillo-Caranza
et al., 2014). We observed distinct tau granular T22 and
TOMA staining in the striatum and in particular within the
putamen but not in the cortex of Huntington’s disease
brains (Fig. 1D). The speciﬁcity of TOMA staining was
tested in Alzheimer’s disease brains (Supplementary Fig. 3).
Biochemical characterization of
sarkosyl-insoluble and soluble tau in
Huntington’s disease
Our observation of AT8-positive pathology in
Huntington’s disease was further supported by western
blot analysis with robust staining of sarkosyl-insoluble
tau from Huntington’s disease brains (Fig. 2A), which
showed a distinct isoform composition and phosphoryl-
ation proﬁle compared to other known tauopathies
(Sergeant et al., 2005). In addition to the characteristic
triplet pattern seen in Alzheimer’s disease with 60, 64
and 69 kDa bands containing 3R- and 4R-tau isoforms,
the insoluble tau from Huntington’s disease brains consist-
ently displayed a more complex pattern of weaker bands
that conﬁrmed the distinct isoform and/or phosphorylation
proﬁles (Fig. 2A). Dephosphorylation of the sarkosyl-insol-
uble tau with lambda-phosphatase, followed by western
blot analysis with a total tau antibody against all the iso-
forms, revealed the underlying isoform composition of the
insoluble tau with a pattern similar to Alzheimer’s disease
samples (Fig. 2A).
To evaluate the level of expression of tau isoforms, the
soluble fraction of tau was also extracted from the cortex
and striatum of Huntington’s disease brains and compared
with control brain samples. All six tau isoforms were
expressed in Huntington’s disease, sporadic tauopathy
and healthy control brains. However in the Huntington’s
disease cases, there was elevated level of the 1N3R and
1N4R isoforms with an electrophoretic pattern closely
resembling tauopathy cases, as compared to the healthy
controls (Fig. 2B).
Altered 4R:3R tau isoform ratio in
Huntington’s disease brains
We next looked at the 3R- and 4R-tau isoform mRNA
levels of expression and, in line with the recent report
from Ferna´ndez-Nogales et al. (2014), found an increased
expression of the 4R-tau isoforms transcripts
(Supplementary Fig. 4A) and a consequent altered 4R:3R
tau transcript ratio in both the cortex (1.261  0.146) and
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striatum (1.446  0.264) of Huntington’s disease cases
versus controls (cortex = 1.037  0.012 and stri-
atum = 1.033  0.059) (Supplementary Fig. 4B).
The presence of 3R- and 4R-tau deposits (Supplementary
Fig. 5A and B), as well as nuclear rod-like structures
(Supplementary Fig. 5C), was also found in our
Huntington’s disease samples. Many of these tau-positive
inclusions contained both 3R- and 4R-tau isoforms
(Supplementary Fig. 5D). The speciﬁcity of the RD3 and
RD4 tau antibodies, respectively for the 3R- and 4R-tau
isoforms was conﬁrmed in known tauopathy cases
(Supplementary Fig. 6).
Co-localization of mutant HTT and
tau in Huntington’s disease brains
We then sought to assess whether there was any
co-localization of mutant HTT aggregates and tau deposits
and/or pathological phosphorylated aggregates, which
would suggest a possible interaction between these two
pathological protein species.
Huntington’s disease cortical and striatal sections were
therefore stained with antibodies speciﬁc for 3R- and 4R-
tau isoforms (RD3 and RD4, respectively), pathologically
phosphorylated tau (AT8 and pS199) and mutant HTT
Figure 1 Tau pathology in Huntington’s disease brains. (A) Immunohistochemical detection of pathological tau aggregates in cortical
(CTX) and striatal (STR) Huntington’s disease tissue [HD8, female, 61 years old (yo)] using the AT8 antibody against phosphorylated tau.
Neuronal inclusions including ring-like perinuclear (black arrow), flame shaped (red arrow), and globular (red arrowhead) morphologies were
observed. Tufted astrocytes and astrocytic plaques (blue arrows) numerous dots and neuropil threads (black arrowhead) were also seen. Scale
bars = 50 mm, insets = 20 mm. (B) Nuclear rod-like tau deposits positive for AT8-immunoreactivity in Huntington’s disease brains (light blue
arrowhead). Scale bar = 20 mm. (C) Phosphorylated tau aggregates detected by immunohistochemistry using AT8 in both cases of patients with
young onset Huntington’s disease (26 and 40 years old). Scale bars = 10 mm (26-years-old) and 50 mm (40-years-old). (D) Immunohistochemistry
using TOMA and T22 antibodies in striatal Huntington’s disease tissue (HD8, female, 61-years-old) showing oligomeric tau inclusions. Scale
bars = 100 mm, insets = 10mm.
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(EM48). The results revealed that some of the mutant HTT
aggregates co-localized with both the 3R- and 4R-tau de-
posits (Fig. 3A and B) and the pathological phosphorylated
tau aggregates (Fig. 3C–F).
Effect of MAPT H2 haplotype on
cognitive decline in patients with
Huntington’s disease
Having established clear evidence of tau pathology in the
brains of patients with Huntington’s disease, and a possible
interaction with mutant HTT aggregates, we then investi-
gated whether MAPT haplotypes—known to alter the
expression of tau isoforms—had any impact on the devel-
opment and clinical expression of Huntington’s disease
using genotype-phenotype analysis.
A total of 960 Huntington’s disease cases were genotyped
for the H1 and H2 haplotypes using the SNP rs9468 and
no marker showed evidence of deviation from Hardy-
Weinberg equilibrium. Complete genetic and clinical data
(including data from all ﬁve cognitive tests) for two inde-
pendent assessments at least a year apart were available for
473 of these individuals who were then included in the
Figure 2 Biochemical characterization of sarkosyl-insoluble and soluble tau in Huntington’s disease brains. (A) Western blot
analysis of the sarkosyl-insoluble tau fraction, before and after dephosphorylation with alkaline phosphatase (pp), with the AT8 and a total tau
antibody in cortical and striatal Huntington’s disease tissues compared to Alzheimer’s disease (AD) cases and healthy controls (CTL). (B) Western
blot analysis of the soluble tau fraction after dephosphorylation with alkaline phosphatase (pp) with a total tau antibody in cortical (CTX) and
striatal (STR) Huntington’s disease tissues, compared to a range of tauopathies (CBD = corticobasal degeneration; PiD = Pick’s disease) and
healthy controls. RecTau molecular weight (kDa): 2N4R (45.9), 2N3R (42.6), 1N4R (42.9), 1N3R (39.7), 0N4R (40.0), 0N3R (36.8).
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analysis. Of these, 60% (n = 283) were H1 homozygotes
(H1/H1) and 40% (n = 190) were H2 carriers (n = 161
H1/H2 and n = 29 H2/H2) (Table 2).
The H1/H1 and H2 carrier groups were demographically
matched (Table 2). The mean annual change in the com-
posite cognitive score was 6.31 points [standard devi-
ation (SD) 23.44] in H1 homozygotes compared to
11.31 points (SD 17.66) in the combined group of H2
carriers [11.61 (SD 17.02) in H1/H2 and 8.75 (SD
11.90) in H2/H2]. Non-parametric comparison conﬁrmed
that this corresponded to a signiﬁcantly higher rate of over-
all cognitive decline in H2 carriers than in H1 homozygotes
(U = 22471, z = 3.029, P = 0.002) (Fig. 4A). Considering
the cognitive subtests individually, there was a signiﬁcantly
higher rate of decline in performance on the Verbal ﬂuency
and Stroop Word tests in H2 carriers than H1 homozy-
gotes, with a trend in the same direction for the other
tests (Table 3). Multivariate analysis conﬁrmed that the
signiﬁcant association between MAPT haplotype and rate
of change in composite cognitive score remained even after
correction for potential confounding variables (Table 4).
Furthermore, the observed effect of MAPT haplotype was
sustained in a subgroup of 107 patients (62 H1/H1, 45 H2
carriers) who had been followed up over a longer time
(mean, 3.52 years; SD, 1.26; U = 915, z = 3.028,
P = 0.002). In contrast, there were no differences associated
with MAPT haplotype on rate of change in motor perform-
ance (Fig. 4B) as measured using the total motor score of
the UHDRS; (Tables 3 and 4) and there was no association
between MAPT haplotype and age at onset (Table 2 and
Supplementary Fig. 7).
There was a signiﬁcant effect of CAG repeat length on
the rate of cognitive change (Table 4), with a higher
number of CAG repeats correlating with an increased
rate of cognitive decline across all participants (Kendall’s
taub = 0.098, P = 0.002). Stratifying the patients accord-
ing to MAPT haplotype revealed that this correlation was
only signiﬁcant in the H2 carriers but not in H1
Figure 3 Mutant huntingtin co-localizes with pathological tau aggregates. (A and B) Mutant HTT aggregates labelled with the EM48
antibody (green) detected within cortical and striatal neurons expressing either 3R-tau or 4R-tau (red). Scale bars in A, A’, B = 25mm;
B’ = 50mm. (C–F) Confocal microscopy images of mutant HTT aggregates labelled with the EM48 antibody (green) within neurons expressing
phosphorylated tau (red) as demonstrated using either the AT8 or pS199 antibodies. The neuronal morphology was further confirmed using the
neuronal marker MAP2 (grey). Aggregates stained for both EM48 and AT8 were also found in the extracellular matrix of the cortex and striatum
of Huntington’s disease cases as shown in D and E. Scale bars in C–E = 30 mm; F = 20mm.
1914 | BRAIN 2015: 138; 1907–1918 R. Vuono et al.








Figure 4 The effect of MAPT haplotypes on cognitive and motor decline in patients with Huntington’s disease. (A) Box and
whisker plot showing rates of change in composite cognitive scores in patients with Huntington’s disease grouped by MAPT haplotype. Median,
interquartile range, and minimum-maximum range are shown. Distributions were compared using Mann–Whitney U-tests. **P5 0.01. (B) Box
and whisker plot showing rates of change in UHDRS Motor scores in patients with Huntingtons’ disease grouped by MAPT haplotype.
(C) Correlation between the CAG repeat length and change in composite cognitive score per year in patients with Huntington’s disease grouped
by MAPT haplotype. Across all participants (n = 473), Kendall’s taub = 0.098, P = 0.002. In H1/H1 (squares; n = 283), Kendall’s taub = 0.063,
P = 0.129; in H2 carriers (triangles; n = 190); Kendall’s taub = 0.148, P = 0.004.
Table 2 Demographic, clinical and genotypic characteristics of the EHDN Huntington’s disease cohort
H1/H1 H1/H2 H2/H2 F/ChiSq Pa
n 283 161 29
Ageb 49.41(12.88) 50.55 (10.98) 48.07 (12.27) 0.727 0.484
CAG repeat length 44.45 (4.74) 43.76 (3.12) 44.86 (5.11) 1.646 0.194
Years since disease onsetb 7.29 (5.01) 7.26 (4.65) 5.33 (4.03) 2.210 0.111
Interval between visits (years) 1.88 (1.16) 1.97 (1.14) 1.83 (0.99) 0.430 0.691
Gender(F:M) 137:146 83:78 11:18 1.876 0.391
UHDRS Motor scoreb 28.11 (15.71) 28.62 (16.38) 26.41 (20.31) 0.231 0.794
UHDRS Functional scoreb 9.31 (2.94) 9.27 (2.89) 9.52 (3.57) 0.087 0.916
Cognitive scoreb 176.88 (60.19) 178.31 (63.20) 185.76 (79.23) 0.271 0.763
Group means are shown with standard deviations in parenthesis. UHDRS = Unified Huntington’s Disease Rating Scale; M = Male; F = Female.
aDerived from independent one-way ANOVA or 2 tests for categorical data.
bAt first visit.
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homozygotes (Fig. 4C). The established negative correlation
between CAG repeat length and age at onset was present
across all participants (Kendall’s taub 0.602, P5 0.001),
and in both H2 carrier and H1 homozygote groups when
considered separately (Supplementary Fig. 7). There was an
association between CAG repeat length and the rate of
motor change, with a longer CAG repeat length predicting
an increased rate of motor decline (Table 4). Age at assess-
ment did not independently inﬂuence the annual rate of
change in the composite cognitive or motor score (Table 4).
Discussion
Tau has been recently reported to be involved in
Huntington’s disease (Ferna´ndez-Nogales et al., 2014;
Blum et al., 2015; Gratuze et al., 2015) although the
exact mechanisms as to how this relates to the clinical fea-
tures of Huntington’s disease, especially the dementia, are
not fully understood.
In this study we establish a key involvement of tau in
Huntington’s disease. In particular, we conﬁrm and extend
the recent ﬁndings of Ferna´ndez-Nogales et al. (2014), by
reporting pathological inclusions containing abnormally
phosphorylated tau protein that co-localizes with mutant
HTT aggregates in the cortex and striatum of human
Huntington’s disease brains. Furthermore, tau pathology
was clearly evident in all our Huntington’s disease cases
and occurred independently of their disease grade, CAG
length and age. The co-occurrence of Alzheimer’s disease
in the ageing Huntington’s disease brains was controlled by
selecting Huntington’s disease cases that were free of any
amyloid-b and tau pathology according to standard pro-
cedures (Braak and Braak, 1991). Furthermore, our bio-
chemical characterization of the sarkosyl-insoluble tau
showed in Huntington’s disease a distinct isoform compos-
ition and phosphorylation proﬁle compared to that of
Alzheimer’s disease.
Finally we observed tau oligomers, which are suggested
to be the most likely neurotoxic tau entity (Gerson and
Kayed, 2013; Castillo-Caranza et al., 2014), only in the
putamen of these brains, which further reinforces the
notion that the presence of tau is a true pathological ﬁnd-
ing in this condition. However, at this time we are unable
to quantify the distribution of tau pathology across the
whole Huntington’s disease brain because of the limited
brain sites we have examined. Therefore, future work is
needed to provide an extensive characterization of patho-
logical tau aggregates in the human Huntington’s disease
brain, which will allow a better mapping of tau pathology
onto clinical features. Nevertheless, our restricted qualita-
tive analysis on the distribution of abnormally
Table 3 Comparisons of rate of change in cognitive and motor scores between H1 homozygotes and H2 carriers
with Huntington’s disease.
Median change (points/year)
H1/H1 H2 carriers U z-score r P
Composite cognitive score 7.00 12.00 22471 3.029 0.139 0.002
Verbal fluency 0.00 0.92 23477 2.339 0.108 0.019
Symbol digit 1.09 1.85 24158 1.871 0.086 0.061
Stroop colour 1.85 2.40 25157 1.186 0.055 0.236
Stroop word 3.00 4.62 23572 2.273 0.105 0.023
Stroop interference 1.03 1.54 25903 0.674 0.031 0.500
UHDRS Motor score 4.85 4.43 25649 0.019 0.001 0.985
Non-parametric comparisons of rate of change in cognitive scores (n = 473) and Unified Parkinson’s Disease Rating Scale (UHDRS) motor scores (n = 462) between H1 homo-
zygotes and H2 carriers with Huntington’s disease. U = Mann Whitney test statistic, r = effect size; P based on two-sided test.
Table 4 Multivariate regression showing factors associated with change in cognitive and motor score in Huntington’s
disease.
Predictor Variable Change in cognitive score Change in motor score
B coefficient P B coefficient P
Constant 36.852 0.038 10.443 0.146
MAPT (H1/H1 versus H2 carriers) 5.291 0.002 0.305 0.647
CAG repeat length 0.815 0.006 0.320 0.008
Sex 0.344 0.834 0.168 0.797
Agea 0.111 0.297 0.021 0.620
Years since onseta 0.120 0.493 0.037 0.591
Multivariate linear regressions with change in composite cognitive score per year (n = 473. R2 = 0.039) and change in UHDRS motor score per year (n = 462. R2 = 0.030) as the
dependent variables.
aPredictor variables represent baseline visit measures.
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phosphorylated tau aggregates and oligomers did reveal a
differential localization in Huntington’s disease brains, with
a higher burden of pathological tau in the insular cortex
compared to other cortical sites and the nucleus accumbens
and inferior/anterior putamen compared to other striatal
sites.
In addition, we show for the ﬁrst time that tau is of
clinical signiﬁcance in Huntington’s disease through our
ﬁnding that MAPT H2 haplotype affects the rate of
cognitive decline in a large cohort of patients with
Huntington’s disease, with evidence of some interaction
with CAG repeat length. Whilst the exact mechanism of
this is not known, coupled to our pathological data, this
supports a possible molecular interaction between these
two proteins, as has been recently suggested by in vitro
and in vivo studies using transgenic animal models of
Huntington’s disease (Blum et al., 2015; Gratuze et al.,
2015).
Thus the importance of our new ﬁndings lies in the un-
equivocal demonstration of tau pathology in the brains of
patients with Huntington’s disease and the effect of MAPT
H2 haplotype on cognitive decline in a large cohort of pa-
tients. This is of particular interest given that the H1 MAPT
haplotype has consistently been shown to be the risk haplo-
type for other neurodegenerative disorders including demen-
tia in Parkinson’s disease (Williams-Gray et al., 2009). It is
also of note that in progressive supranuclear palsy, cortico-
basal degeneration and Parkinson’s disease, the H1 haplotype
has been associated with increased 4R-tau isoforms while we
now report the opposite association in Huntington’s disease.
One possible explanation for this may relate to the binding
and sequestration of splicing factor-6 (SRSF6/SRp55) by the
CAG repeat in mutant HTT mRNA (Ferna´ndez-Nogales
et al., 2014). This may result in a more profound allele-spe-
ciﬁc effect on spliceosome assembly during transcription of
theH2 allele, giving rise to the large increase in 4R-taumRNA
that we observe in Huntington’s disease, especially given that
SRSF6 is involved inMAPT exon 10 splicing (Yin et al., 2012)
and co-localizes with mutant HTT inclusions (Ferna´ndez-
Nogales et al., 2014).
In summary, we show a novel role of tau in the patho-
logical process and clinical expression of Huntington’s dis-
ease. Further studies are needed to elucidate the exact
mechanisms by which this occurs, which in turn may
open up new therapeutic approaches for treating this cur-
rently incurable condition.
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